Novavax taps Japan's AGC to make ingredient in COVID-19 shot
Manufacturer produces compound for boosting vaccine candidate's effectiveness
Novavax's COVID-19 candidate vaccine is administered to a clinical trial participant in Australia in this Australian Broadcasting Corp. image. (Photo courtesy of Novavax)
TOKYO -- Chemical and materials group AGC has started producing an additive for a coronavirus vaccine candidate being developed by U.S. company Novavax, the Japanese manufacturer said Thursday.
U.S. subsidiary AGC Biologics has been contracted to produce an adjuvant, a compound that improves a vaccine's effectiveness. The agent is being manufactured at a plant in Denmark.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30